Skip to main content
Log in

Treatment of Tardive Dyskinesia with Aripiprazole

  • Published:
Neurotoxicity Research Aims and scope Submit manuscript

Abstract

Tardive dyskinesia (TD) is a severe and potential irreversible side effect of antipsychotic treatment. Treatment of established TD is often unsuccessful. In this article, we report three cases of psychogeriatric patients who suffered from TD as a side effect of long-term treatment with haloperidol that resolved after switching treatment to aripiprazole. Potential psychopharmacological mechanisms explaining this finding are briefly discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abbasian C, Power P (2009) A case of aripiprazole and tardive dyskinesia. J Psychopharmacol 23:214–215

    Article  CAS  PubMed  Google Scholar 

  • Casey DE (2004) Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatr 65:25–28

    CAS  Google Scholar 

  • Correll CU, Schenk EM (2008) Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatr 21:151–156

    Article  Google Scholar 

  • Duggal HS (2003) Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatr 48:771–772

    Google Scholar 

  • Grant MJ, Baldessarini RJ (2005) Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother 39:1953

    PubMed  Google Scholar 

  • Grunder G, Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatr 60:974–977

    Article  PubMed  Google Scholar 

  • Huang NY, Kostrzewa RM, Li C, Perry KW, Fuller RW (1997) Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenates. J Pharmacol Exp Ther 280:268–276

    CAS  PubMed  Google Scholar 

  • Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y (1997) Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 321:105–111

    Article  PubMed  Google Scholar 

  • Klawans HL, Tanner CM, Goetz CG (1988) Epidemiology and pathophysiology of tardive dyskinesia. Adv Neurol 49:185–197

    CAS  PubMed  Google Scholar 

  • Kostrzewa RM, Huang NY, Kostrzewa JP, Nowak P, Brus R (2007) Modeling tardive dyskinesia: predictive 5-HT2C receptor antagonist treatment. Neurotox Res 11:41–50

    Article  CAS  PubMed  Google Scholar 

  • Lykouras L, Rizos E, Gournellis R (2007) Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatr 31:1535–1536

    Article  CAS  Google Scholar 

  • Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatr 164:1411–1417

    Article  PubMed  Google Scholar 

  • Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L (2005) Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatr 50:703–714

    Google Scholar 

  • Maytal G, Ostacher M, Stern TA (2006) Aripiprazole-related tardive dyskinesia. CNS Spectr 11:435–439

    PubMed  Google Scholar 

  • Anonymous (2008) Aripiprazole improves neuroleptic-associated tardive dyskinesia, but it does not meliorate psychotic symptoms. Prog Neuropsychopharmacol Biol Psychiatr 32:1342–1343

    Article  Google Scholar 

  • Peritogiannis V, Tsouli S, Zafiris S, Pappas D, Mavreas V (2006) Improvement of tardive dyskinesia following amisulpride treatment. Prog Neuropsychopharmacol Biol Psychiatr 30:748–750

    Article  CAS  Google Scholar 

  • Sharma A, Ramaswamy S, Dewan VK (2005) Resolution of ziprasidone-related tardive dyskinesia with a switch to aripiprazole. Prim Care Companion J Clin Psychiatr 7:36

    Article  Google Scholar 

  • Soares-Weiser K, Fernandez HH (2007) Tardive dyskinesia. Semin Neurol 27:159–169

    Article  PubMed  Google Scholar 

  • Tarsy D, Baldessarini RJ (2006) Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 21:589–598

    Article  PubMed  Google Scholar 

  • Waddington JL, Cross AJ, Gamble SJ, Bourne RC (1983) Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 220:530–532

    Article  CAS  PubMed  Google Scholar 

  • Witschy JK, Winter AS (2005) Improvement in tardive dyskinesia with aripiprazole use. Can J Psychiatr 50:188

    Google Scholar 

Download references

Acknowledgements

This work was supported in part by the Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ricardo S. Osorio.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Osorio, R.S., Agüera-Ortiz, L., Hurtado de Mendoza, A. et al. Treatment of Tardive Dyskinesia with Aripiprazole. Neurotox Res 17, 432–434 (2010). https://doi.org/10.1007/s12640-009-9123-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12640-009-9123-0

Keywords

Navigation